ArticleNPJ breast cancer2023

High-dose alkylating chemotherapy in BRCA-altered triple-negative breast cancer: the randomized phase III NeoTN trial.

Sonja Vliek et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.